Stock PV3B EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Real-time Estimate Tradegate
Other stock markets
 02:51:44 03/07/2024 pm IST 		5-day change 1st Jan Change
7.449 EUR -2.40% Intraday chart for EyePoint Pharmaceuticals, Inc. -8.44% -66.14%
26/06 EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024 CI
26/06 Transcript : EyePoint Pharmaceuticals, Inc. - Special Call

Insiders

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board
CI
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer
MT
EyePoint Pharmaceuticals, Inc. Announces Executive Changes
CI
Eyepoint Pharmaceuticals Insider Sold Shares Worth $1,265,539, According to a Recent SEC Filing
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $660,370, According to a Recent SEC Filing
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $297,621, According to a Recent SEC Filing
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $409,790, According to a Recent SEC Filing
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $795,191, According to a Recent SEC Filing
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $484,124, According to a Recent SEC Filing
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing
MT
EyePoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $990,000, According to a Recent SEC Filing
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $415,200, According to a Recent SEC Filing
MT
EyePoint Pharmaceuticals, Inc. Announces Executive Changes
CI
Akari Therapeutics Names Wendy DiCicco Interim Finance Chief
MT
EyePoint Pharmaceuticals Names Jay Duker CEO; Shares Climb
MT
EyePoint Pharmaceuticals Names Jay Duker CEO
MT
Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes
CI
Eyepoint Pharmaceuticals, Inc. Announces Executive Changes
CI
Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. PV3B Stock
  5. News EyePoint Pharmaceuticals, Inc.
  6. Insiders